Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Pike

Showing results (191-200 of 198) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 198 results.
European Urology Oncology|August 6, 2024
Clinical Outcomes and Targeted Genomic Analysis of Renal Cell Carcinoma Brain Metastases Treated with Stereotactic RadiosurgeryJennifer Ma, Luke Del Balzo, Henry Walch, et al.
Neuro-Oncology|September 2, 2025
Genomics correlates of brain metastasis and progression in colorectal cancerChengcheng Gui, Henry S Walch, Kirin D Mueller, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2024
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancerSi-Yang Liu, Tatiana Erazo, Justin Jee, et al.
Science Advances|June 26, 2018
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor modelsStephen T Durant, Li Zheng, Yingchun Wang, et al.
Molecular Cancer Therapeutics|May 18, 2018
Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in MiceJeremy Karlin, Jasmine Allen, Syed F Ahmad, et al.
Journal of Medicinal Chemistry|December 11, 2020
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological MalignanciesBernard Barlaam, Robert Casella, Justin Cidado, et al.
Cancer Discovery|June 3, 2024
Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early DetectionPeter J Mazzone, Peter B Bach, Jacob Carey, et al.
Biorxiv : the Preprint Server for Biology|August 20, 2025
Integrated histopathologic modeling of detailed tumor subtypes and actionable biomarkersKevin M Boehm, Madison Darmofal, Arfath Pasha, et al.
Pageof 20

Showing results (191-200 of 198) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 198 results.
European Urology Oncology|August 6, 2024
Clinical Outcomes and Targeted Genomic Analysis of Renal Cell Carcinoma Brain Metastases Treated with Stereotactic RadiosurgeryJennifer Ma, Luke Del Balzo, Henry Walch, et al.
Neuro-Oncology|September 2, 2025
Genomics correlates of brain metastasis and progression in colorectal cancerChengcheng Gui, Henry S Walch, Kirin D Mueller, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2024
Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancerSi-Yang Liu, Tatiana Erazo, Justin Jee, et al.
Science Advances|June 26, 2018
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor modelsStephen T Durant, Li Zheng, Yingchun Wang, et al.
Molecular Cancer Therapeutics|May 18, 2018
Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in MiceJeremy Karlin, Jasmine Allen, Syed F Ahmad, et al.
Journal of Medicinal Chemistry|December 11, 2020
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological MalignanciesBernard Barlaam, Robert Casella, Justin Cidado, et al.
Cancer Discovery|June 3, 2024
Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early DetectionPeter J Mazzone, Peter B Bach, Jacob Carey, et al.
Biorxiv : the Preprint Server for Biology|August 20, 2025
Integrated histopathologic modeling of detailed tumor subtypes and actionable biomarkersKevin M Boehm, Madison Darmofal, Arfath Pasha, et al.
Pageof 20